Filoviruses
The filovirus family includes some of the world’s most deadly pathogens, including Zaire ebolavirus – commonly known as Ebola virus. CEPI’s filovirus investments focus on expanding access to licensed vaccines against Ebola virus, pioneering the development of broadly protective filovirus vaccines and a filovirus vaccine library, and supporting clinical trials of vaccine candidates for Marburg virus and Sudan ebolavirus during outbreaks.
Ebola
CEPI has supported the generation of clinical trial data for both licensed Ebola virus vaccines, including funding studies to help expand access for vulnerable populations including people living with HIV, pregnant women and infants. CEPI is now focused on helping to make the licensed Ebola vaccines sustainable for the future.
Broadly protective filovirus vaccines
CEPI is pioneering research into vaccines that could protect against multiple known filoviruses, with co-funding from the European Union’s Horizon Programme. The programme is making a vital contribution to the 100 Days Mission by generating important scientific knowledge for a ‘filovirus vaccine library’, intended to accelerate vaccine development against a future filovirus Disease X.
Vaccines against other filoviruses
Currently no approved vaccines exist for Sudan ebolavirus or Marburg virus, both of which have caused multiple deadly disease outbreaks in Africa in recent years. CEPI has supported clinical trials of monovalent vaccine candidates against these filoviruses as part of country-led responses in Rwanda and Uganda. The organisation is funding the development of international antibody standards for Marburg virus – now established – and Sudan ebolavirus. These important scientific tools will help researchers to assess and compare the performance of experimental vaccines against the diseases.
Filovirus news
Filovirus news
Preparedness in practice: Rwanda’s record-breaking Marburg response
CEPI’s outbreak response experts reflect on how Rwanda was able to implement an emergency trial of a Marburg vaccine just 10 days after the outbreak was declared.
CEPI and partners collaborate to advance key tools for Sudan ebolavirus vaccine research
International antibody standard will standardize assessment of vaccines against SUDV, contributing to eventual licensure.
Searching for Ebola's hideout
After the West African epidemic, Ebola disappeared. But having hidden somewhere – maybe in forest animals, maybe closer to home – it’s now re-emerged in the Democratic Republic of the Congo. Leigh Cowart joins the hunt for its hiding place.
